CBMG's AlloJoin therapy for KOA becomes first stem cell drug application approved in China
Cellular Biomedicine Group announced that its off-the-shelf allogeneic adipose-derived mesenchymal progenitor cell AlloJoin® therapy for Knee Osteoarthritis has been approved as the first stem cell KOA drug application in China for a Phase II clinical trial. January 17, 2019